

EMA/635452/2011

European Medicines Agency decision P/200/2011

of 5 August 2011

on the acceptance of a modification of an agreed paediatric investigation plan for dasatinib (Sprycel) (EMA-000567-PIP01-09-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This Decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/200/2011

of 5 August 2011

on the acceptance of a modification of an agreed paediatric investigation plan for dasatinib (Sprycel) (EMA-000567-PIP01-09-M02) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/225/2009 issued on 3 November 2009, the decision P/31/2010 issued on 5 March 2010,

Having regard to the application submitted by Bristol-Myers Squibb Pharma EEIG on 29 April 2011 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral and a waiver,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 15 July 2011, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1.

² OJ L 136, 30.4.2004, p. 1.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for dasatinib (Sprycel), film-coated tablet, age-appropriate oral formulation, oral use, including changes to the deferral are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Bristol-Myers Squibb Pharma EEIG, Uxbridge Business Park, Sanderson Road, Uxbridge UB8 1DH, United Kingdom.

Done at London, 5 August 2011

For the European Medicines Agency
Andreas Pott
Acting Executive Director
(Signature on file)



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

EMA/PDCO/496606/2011

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-000567-PIP01-09-M02

Scope of the application

Active substance(s):

Dasatinib

Invented name:

Sprycel

Condition(s):

Treatment of Philadelphia chromosome (BCR-ABL translocation)-positive chronic myeloid leukaemia

Treatment of Philadelphia chromosome (BCR-ABL translocation)-positive acute lymphoblastic leukaemia

Authorised indication(s):

See Annex II

Pharmaceutical form(s):

Film-coated tablet

Age-appropriate oral formulation

Route(s) of administration:

Oral use

Name/corporate name of the PIP applicant:

Bristol-Myers Squibb Pharma EEIG

Information about the authorised medicinal product:

See Annex II



Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Bristol-Myers Squibb Pharma EEIG submitted to the European Medicines Agency on 29 April 2011 an application for modification of the agreed paediatric investigation plan with a deferral and a waiver as set out in the European Medicines Agency's decision P/225/2009 issued on 3 November 2009 and the decision P/31/2010 issued on 5 March 2010.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 18 May 2011.

Scope of the modification

Some measures and timelines of the Paediatric Investigation Plan and the deferral have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Norwegian Paediatric Committee member agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan and the subset(s) of the paediatric population and condition(s) covered by the waiver are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

London, 15 July 2011

On behalf of the Paediatric Committee
Dr Daniel Brasseur, Chairman
(Signature on file)

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed Paediatric Investigation Plan

1. Waiver

1.1. Condition: Treatment of Philadelphia chromosome (BCR-ABL translocation)-positive chronic myeloid leukaemia

The waiver applies to:

- Children from birth to less than 1 year of age;
- For film-coated tablet and age-appropriate oral formulation;
- On the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset.

1.2. Condition: Treatment of Philadelphia chromosome (BCR-ABL translocation)-positive acute lymphoblastic leukaemia

The waiver applies to:

- Children from birth to less than 1 year of age;
- For film-coated tablet and age-appropriate oral formulation;
- On the grounds that the disease or condition for which the specific medicinal product is intended does not occur in the specified paediatric subset.

2. Paediatric Investigation Plan

2.1. Condition: Treatment of Philadelphia chromosome (BCR-ABL translocation)-positive chronic myeloid leukaemia

2.1.1. Indication(s) targeted by the PIP

Treatment of Philadelphia chromosome (BCR-ABL translocation)-positive (Ph+) chronic myeloid leukaemia.

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From 1 year to less than 18 years of age.

2.1.3. Pharmaceutical form(s)

Film-coated tablet, oral use.

Age-appropriate oral formulation, oral use.

2.1.4. Studies

Area	Number of studies	Description
Quality	1	Study 1: Age-appropriate formulation for oral use (such as liquid or multi-particulate formulation)

Area	Number of studies	Description
Non-clinical	0	Not applicable
Clinical	3	Study 2: Open-label, multi-centre, dose-escalation trial to evaluate pharmacokinetics and safety of dasatinib in children from 2 years to less than 18 years of age (and in adults) with recurrent or refractory solid tumour or imatinib-resistant Ph+ leukaemia Study 3: Open-label, multi-centre, dose-escalation trial to evaluate pharmacokinetics and safety of dasatinib in children from 1 years to less than 18 years of age with Ph+ chronic myeloid leukaemia or acute leukaemia Study 4: Open-label, multi-centre trial to evaluate pharmacokinetics, safety and efficacy of dasatinib in children from 1 years to less than 18 years of age with Ph+ chronic myeloid leukaemia of all phases (including treatment-naïve patients in chronic phase) or relapsed / refractory Ph+ acute lymphoblastic leukaemia

2.2. Condition: Treatment of Philadelphia chromosome (BCR-ABL translocation)-positive acute lymphoblastic leukaemia

2.2.1. Indication(s) targeted by the PIP

Treatment of Philadelphia chromosome (BCR-ABL translocation)-positive (Ph+) acute lymphoblastic leukaemia.

2.2.2. Subset(s) of the paediatric population concerned by the paediatric development

From 1 year to less than 18 years of age.

2.2.3. Pharmaceutical form(s)

Film-coated tablet, oral use.

Age-appropriate oral formulation, oral use.

2.2.4. Studies

Area	Number of studies	Description
Quality	1	Study 1 as for condition treatment of Philadelphia chromosome (BCR-ABL translocation)-positive chronic myeloid leukaemia
Non-clinical	0	Not applicable
Clinical	5	Study 2 as for condition treatment of Philadelphia chromosome (BCR-ABL translocation)-positive chronic myeloid leukaemia

Area	Number of studies	Description
		Study 3 as for condition treatment of Philadelphia chromosome (BCR-ABL translocation)-positive chronic myeloid leukaemia Study 4 as for condition treatment of Philadelphia chromosome (BCR-ABL translocation)-positive chronic myeloid leukaemia Study 5: Open-label, multi-centre trial evaluating safety and tolerability of dasatinib in combination with multi-agent chemotherapy in children from 1 year to less than 18 years of age (and adults) with newly-diagnosed Ph+ acute lymphoblastic leukaemia Study 6: Open-label, multi-centre, historically-controlled trial to evaluate safety and efficacy of dasatinib plus chemotherapy compared to chemotherapy alone and compared to imatinib plus chemotherapy in children from 1 year to less than 18 years of age with newly diagnosed Ph+ acute lymphoblastic leukaemia

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety and efficacy issues in relation to paediatric use:	Yes
Date of completion of the paediatric investigation plan:	By December 2017
Deferral for one or more studies contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Condition(s) and authorised indication(s):

1. Treatment of Philadelphia chromosome (BCR-ABL translocation)-positive chronic myeloid leukaemia

Authorised indications:

Sprycel is indicated for the treatment of adult patients with:

- newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase.
- chronic, accelerated or blast phase CML with resistance or intolerance to prior therapy including imatinib mesilate.

2. Treatment of Philadelphia chromosome (BCR-ABL translocation)-positive acute lymphoblastic leukaemia

Authorised indications:

Sprycel is indicated for the treatment of adult patients with:

- Ph+ acute lymphoblastic leukaemia (ALL) and lymphoid blast CML with resistance or intolerance to prior therapy.

EU Number	(Invented) name	Strength	Pharmaceutical Form	Route of Administration	Packaging	Package size
EU/1/06/363/001	Sprycel	20 mg	Film-coated tablet	Oral use	bottle (HDPE)	60 tablets
EU/1/06/363/002	Sprycel	50 mg	Film-coated tablet	Oral use	bottle (HDPE)	60 tablets
EU/1/06/363/003	Sprycel	70 mg	Film-coated tablet	Oral use	bottle (HDPE)	60 tablets
EU/1/06/363/004	Sprycel	20 mg	Film-coated tablet	Oral use	blister (alu/alu)	56 tablets
EU/1/06/363/005	Sprycel	50 mg	Film-coated tablet	Oral use	blister (alu/alu)	56 tablets
EU/1/06/363/006	Sprycel	70 mg	Film-coated tablet	Oral use	blister (alu/alu)	56 tablets
EU/1/06/363/007	Sprycel	20 mg	Film-coated tablet	Oral use	blister (alu/alu)	60 x 1 tablet (unit dose)
EU/1/06/363/008	Sprycel	50 mg	Film-coated tablet	Oral use	blister (alu/alu)	60 x 1 tablet (unit dose)
EU/1/06/363/009	Sprycel	70 mg	Film-coated tablet	Oral use	blister (alu/alu)	60 x 1 tablet (unit dose)
EU/1/06/363/010	Sprycel	100 mg	Film-coated tablet	Oral use	bottle (HDPE)	30 tablets
EU/1/06/363/011	Sprycel	100 mg	Film-coated tablet	Oral use	blister (alu/alu)	30 x 1 tablet (unit dose)
EU/1/06/363/012	Sprycel	80 mg	Film-coated tablet	Oral use	bottle (HDPE)	30 tablets

EU Number	(Invented) name	Strength	Pharmaceutical Form	Route of Administration	Packaging	Package size
EU/1/06/363/013	Sprycel	80 mg	Film-coated tablet	Oral use	blister (alu/alu)	30 x 1 tablet (unit dose)
EU/1/06/363/014	Sprycel	140 mg	Film-coated tablet	Oral use	bottle (HDPE)	30 tablets
EU/1/06/363/015	Sprycel	140 mg	Film-coated tablet	Oral use	blister (alu/alu)	30 x 1 tablet (unit dose)